Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

40%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 4Post-market surveillance

3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Other(1)

Detailed Status

Completed3

unknown1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (40.0%)

Phase 43 (60.0%)

Trials by Status

unknown120%

completed360%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

recruitingphase_4

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

NCT04861103

unknownphase_4

Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

NCT01687491

Clinical Trials (5)

Showing 5 of 5 trials

NCT04861103Phase 4

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

Recruiting

NCT06133803Phase 4

Lovenox With Aspirin in Thawed Blastocyst Transfer

Unknown

NCT04552067Phase 1

Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients

Completed

NCT02152423Phase 1

Enoxamed Study in the Treatment of Acute Coronary Syndromes

Completed

NCT01687491Phase 4

Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5